CLAIM AMENDMENTS

1. - 39. (canceled)

40. (new) A compound of formula A or formula B:

where

R¹, R², and R³ are independently, hydrogen, or optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl(lower alkyl), halo(lower alkyl), -CF3, halogen, nitro, -CN, -OR9, -SR9, -NR9R¹0, -NR9(carboxy(lower alkyl)), -C(=O)R9, -C(=O)CR9, -C(=O)NR9R¹0, -OC(=O)R9, -SO2R9, -OSO2R9, -SO2NR9R¹0, -NR9SO2R¹0 or -NR9C(=O)R¹0, where R9 and R¹0 are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C1-2 alkyl)2, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aryloxy, heteroaryl, heteroaryl(lower alkyl), or R9 and R¹0 together are -(CH2)4-6- optionally interrupted by one O, S, NIH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C1-2 alkyl) group,

R⁴ and R⁵ are independently, hydrogen, lower alkyl optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted aryl(lower alkyl), or, together, are -(CH₂)₂₋₄-,

R6 is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl(lower alkyl), optionally substituted heteroaryl(lower alkyl), -C(=O)R¹¹, -C(=O)OR¹¹, -C(=O)NR¹¹R¹², -SO₂R¹¹, or -SO₂NR¹¹R¹², where R¹¹ and R¹² are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), aryl, optionally substituted aryloxy, heteroaryl, heteroaryl(lower alkyl), or R¹¹ and R¹² together are -(CH₂)4-6-,

650 8457800

App. No. 10/716,363 Page 3

or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

- 41. (new) The compound of claim 40, where said compound is a compound of Formula A or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.
- 42. (new) The compound of claim 40, where said compound is a compound of Formula B or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.
- 43. (new) The compound of claim 40, where R¹ is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, -OR9, -NR9R¹0, -C(=O)OR9, -C(=O)NR9R¹0, -SO₂NR9R¹0, or -NR9C(=O)R¹0, where R9 and R¹0 are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C₂₂ alkyl)₂, lower alkyl(optionally substituted heterocycloalkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl).
- The compound of claim 43, where R¹ is optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted aryl(lower alkyl), halogen, -OR9, -NR9R¹0, -C(=O)OR9, -C(=O)NR9R¹0, -SO2NR9R¹0, or -NR9C(=O)R¹0, where R9 and R¹0 are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C₁-2 alkyl)2, lower alkyl(optionally substituted heterocycloalkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl).
- 45. (new) The compound of claim 40, where R² is hydrogen, optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, -OR³, -NR³(carboxy(lower alkyl)), -C(=O)NR³R¹0, -SO₂NR³R¹0, or -NR³C(=O)R¹0, where R³ and R¹0 are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C₁-₂ alkyl)₂, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted aryloxy, heteroaryl, heteroaryl(lower alkyl), or R³ and R¹0 together are -(CH₂)+6- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C₁-₂ alkyl) group.
- 46. (new) The compound of claim 45, where R² is optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkyl,

App. No. 10/716,363

optionally substituted aryl(lower alkyl), halogen, -OR?, -NR?(carboxy(lower alkyl)), -C(=O)OR?, -C(=O)NR?R¹0, -SO2NR?R¹0, or -NR?C(=O)R¹0, where R² and R¹0 are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C₁-2 alkyl)₂, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted aryloxy, heteroaryl, heteroaryl(lower alkyl), or R² and R¹0 together are -(CH₂)₄-6- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C₁-2 alkyl) group.

- 47. (new) The compound of claim 40, where R³ is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), halogen, -OR9, -NR9R¹0, -C(=O)OR9, or -C(=O)NR9R¹0, where R9 and R¹0 are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C₁-2 alkyl)2, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted aryloxy, heteroaryl(lower alkyl), or R9 and R¹0 together are -(CH₂)+6- optionally interrupted by one O, S, NH, N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C₁-2 alkyl) group.
- 48. (new) The compound of claim 47, where R³ is optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, optionally substituted aryl(lower alkyl), halo(lower alkyl), halogen, -OR9, -NR9R¹0, -C(=O)OR9, or -C(=O)NR9R¹0, where R³ and R¹0 are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-N(C₁-2 alkyl)₂, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted aryloxy, heteroaryl(lower alkyl), or R³ and R¹0 together are -(CH₂)4-6- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C₁-2 alkyl) group.
- 49. (new) The compound of claim 40, where R⁴ and R⁵ are independently, hydrogen or lower alkyl.
- The compound of claim 40, where R⁶ is hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, cycloalkyl (lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl (lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl (lower alkyl), -C(=O)R¹¹, -C(=O)NR¹¹R¹², -SO₂R¹¹, or

-SO₂NR¹¹R¹², where R¹¹ and R¹² are independently, hydrogen, optionally substituted lower alkyl, cycloalkyl (lower alkyl), aryl, heteroaryl (lower alkyl), or R¹¹ and R¹² together are -(CH₂)₄₋₆-.

51. (new) The compound of claim 40 that is a compound of formula Aa or formula Ba:

where:

R1, R2, R3, R4, and R5 are as defined in claim 40,

R¹³ is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), -CF₃, halogen, nitro, -CN, -OR¹⁵, -SR¹⁵, -NR¹⁵R¹⁶, -C(=O)R¹⁵, -C(=O)OR¹⁵, -C(=O)R¹⁵, -SO₂R¹⁵, -SO₂NR¹⁵R¹⁶, -NR¹⁵SO₂R¹⁶ or -NR¹⁵C(=O)R¹⁶, where R¹⁵ and R¹⁶ are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, -CF₃, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryloxy, optionally substituted heteroaryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), or, together, are -(CH₂)₄₋₆- optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group,

each R¹⁴ is independently selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, -CF₃, -OR¹⁷, -NR¹⁷R¹⁸, -C(=O)R¹⁸, -C(=O)NR¹⁷R¹⁸, where R¹⁷ and R¹⁸ are independently, hydrogen, lower alkyl, alkenyl, alkynyl, -CF₃, optionally substituted heterocycloalkyl, cycloalkyl (lower alkyl), optionally substituted aryl, optionally substituted aryloxy, heteroaryl (lower alkyl), or, together, are -(CH₂)₄₋₆-, optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group, and

where n is an integer of 0 to 4,

or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers.

- 52. (new) The compound of claim 51, where said compound is a compound of Formula Aa or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers.
- 53. (new) The compound of claim 51, where said compound is a compound of Formula Ba or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers.
- 54. (new) The compound of claim 51, where R¹³ is -OR¹⁵, and R¹⁵ is hydrogen, lower alkyl optionally substituted with -C(=O)OR¹⁹, where R¹⁹ is hydrogen or lower alkyl, alkenyl, alkynyl, -CF₃, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heteroaryl(lower alkyl).
- The compound of claim 51, where R¹³ is hydrogen, optionally substituted lower alkyl, alkenyl, heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), -CF₃, halogen, nitro, -CN, -OR¹⁵, -SR¹⁵, -NR¹⁵R¹⁶, -C(=O)R¹⁵, -C(=O)OR¹⁵, -C(=O)NR¹⁵R¹⁶, -OC(=O)R¹⁵, -SO₂R¹⁵, -SO₂NR¹⁵R¹⁶, or -NR¹⁵C(=O)R¹⁶, where R¹⁵ and R¹⁶ are independently, hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl) or, together, are -(CH₂)₄₋₆- optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group.
- The compound of claim 55, where R¹³ is optionally substituted lower alkyl, alkenyl, heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), -CF₃, halogen, nitro, -CN, -OR¹⁵, -SR¹⁵, -NR¹⁵R¹⁶, -C(=O)R¹⁵, -C(=O)OR¹⁵, -C(=O)NR¹⁵R¹⁶, -OC(=O)R¹⁵, -SO₂NR¹⁵R¹⁶, or -NR¹⁵C(=O)R¹⁶, where R¹⁵ and R¹⁶ are independently, hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl) or, together, are -(CH₂)₄₋₆- optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group.

- 57. (new) The compound of claim 51, where R¹⁴ is independently selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, -CF₃, -OR¹⁷ -NR¹⁷R¹⁸, -C(=O)R¹⁸, -C(=O)OR¹⁸, -C(=O)NR¹⁷R¹⁸, where R¹⁷ and R¹⁸ are, independently, hydrogen, lower alkyl, alkenyl, or optionally substituted aryl.
- 58. (new) The compound of claim 56, where n is an integer of 1 to 2.

TELIK INC

- 59. (new) The compound of claim 58, where n is 1.
- 60. (new) The compound of claim 51, where R1 is lower alkyl.
- 61. (new) The compound of claim 51, where R² and R³ are independently selected from hydrogen, lower alkyl, halogen, OR⁹, -NR⁹R¹⁰, where R⁹ and R¹⁰ are independently lower alkyl, substituted lower alkyl, or substituted aryl, or R⁹ and R¹⁰ together are -(CH₂)₄₋₆- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C₁₋₂ alkyl) group.
- 62. (new) The compound of claim 56, where R¹³ is independently selected from halogen, optionally substituted aryl, -CF₃, -CH₃, -CN, -OR¹⁵, -C(=O)R¹⁵, -C(=O)OR¹⁵, -C(=O)NR¹⁵R¹⁶, or -CO₂H.
- 63. (new) The compound of claim 51, where R¹⁴ is independently selected from halogen, optionally substituted lower alkyl, -CF₃, -OR¹⁷, aryl, heteroaryl, -NR¹⁷R¹⁸, -C(=O)R¹⁷, -C(=O)OR¹⁷, -C(=O)NR¹⁷R¹⁸, or -CO₂H, where R¹⁷ and R¹⁸ are, independently, lower alkyl, substituted lower alkyl, or substituted aryl, or, together, are -(CH₂)₄₋₆- optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group.
- 64. (new) The compound of claim 51, where R² is 4-methylpiperazinyl, R¹³ is 3-CF₃, and R¹⁴ is 4-F.
- 65. (new) A pharmaceutical composition comprising:
- (a) a therapeutically effective amount of a compound of claim 40; and
- (b) a pharmaceutically acceptable excipient.
- 66. (new) The pharmaceutical composition of claim 65, further comprising an antiinflammatory drug, cytokine, or immunomodulator.

TELIK INC

App. No. 10/716,363 Page 8

A method of treating an allergic, inflammatory, or autoimmune disorder or disease, 67. (new) comprising administering a therapeutically effective dose of at least one compound of claim 40 to a mammal in need of such treatment.

- The method of claim 67, where the compound is administered in combination with 68. (new) an anti-inflammatory drug, cytokine, or immunomodulator.
- 69. (new) The method of claim 67, where the allergic, inflammatory, or autoimmune disorder or disease is selected from asthma, atherosclerosis, glomerulonephritis, pancreatitis, restenosis, rheumatoid arthritis, diabetic nephropathy, pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, and transplant rejection.
- The method of claim 67, where the allergic, inflammatory, or autoimmune disorder 70. (new) or disease is associated with lymphocyte and/or monocyte accumulation.
- A method of inhibiting leukocyte migration, comprising administering a 71. (new) therapeutically effective dose of at least one compound of claim 40 to a mammal in need of such treatment.